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Figure 1. Impact of ABO incompatibility on OS of 143 AML/MDS patients who
underwent RIC allo HCT.
Figure 2. Impact of HLA matching on OS in 146 AML/MDS patients who un-
derwent RIC allo HCT.
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Background: Reduced intensity conditioning (RIC) has
expanded allogeneic hematopoietic stem cell transplantation
(HCT) to elderly patients and to those with additional
comorbidities. There is inconclusive evidence suggesting
that the risk of adverse events, such as pure red cell aplasia
(PRCA), delayed engraftment, or shortened survival, is
increased with ABO incompatibility. We sought to better
elucidate these issues.
Methods: After IRB approval, consecutive patients with
myeloid neoplasms (MDS and AML) who underwent their
ﬁrst RIC allo HCT from 2005 to 2014 were identiﬁed. All
clinical and transplant data were retrospectively abstracted.
Conditioning regimens, GVHD prophylaxis and transfusions
were according to institutional standards.
Results: Of 148 patients (median age 61, male 62%), 97 (65%)
had AML, 29 (20%) had MDS with excess blasts and 22 (15%)
had MDS without excess blasts. At last follow up, 31(21%)
relapses and 63 (48%) deaths were noted (median follow up
17 months).
Transfusion and engraftment data are shown in Table 1.
PRCA was diagnosed in 6 (20% of the major mismatch
group), all of whom had an A to O mismatch. ABO major
mismatches had higher RBC and PLT transfusion needs at
100 days (p<0.0001 for RBC and 0.004 for PLT transfusion),
and at 1 year (p¼0.004 for RBC and 0.007 for PLT trans-
fusion), as well as delayed RBC (p<0.001) and PLT
(p<0.001) engraftment compared with the ABO compat-
ible group. This was true even after excluding patients
with PRCA. PMN engraftment was not affected by ABO
compatibility.
Therewasnodifference inoverall survival (OS) among the3
groups (p¼0.51) (Figure1). For the total cohort,mediandisease
free survival (DFS) and OS estimates were 43 and 44 months,
respectively. Relapse rate (RR) was 22%, and non-relapse
mortality (NRM)was21%at theendof1year.Acuteandchronic
GVHDwere seen in 58% and 59%, respectively. After univariate
and multivariate analyses, the only factors with impact on OS
were the degree of HLAmatching (p¼0.005) (Figure 2) and the
presence of chronicGVHD (p<0.0001) (Figure 3). Therewas no
difference in DFS (p¼0.97) or OS (p¼0.78) between patients
with AML and MDS.
Conclusions: Our analysis of a large cohort of AML/MDS
patients who underwent RIC allo HCT shows that ABO
incompatibility hasno impactonDFS,OS, RR,NRM, or acute and
chronic GVHD. However, higher RBC and PLT transfusion needs,
and PRCA are frequent complications adding to the morbidity.Table 1
Transfusion and engraftment data according to ABO compatibility groups in
148 AML/MDS patients who underwent RIC allo-HSCT
Total patients: 148* ABO
Compatible
(n[89)
Major
Mismatch
(n[29)
Minor
Mismatch
(n[25)
P.
Value
Median RBC units
100 days 3 12 2 <0.0001
1 year 5 17.5 3.5 0.002
Median PLT units
100 days 3.5 10 3 0.008
1 year 5 15 4 0.013
Median days to
engraftment
RBC 11 29 9 <0.0001
PLT 11 14 11 0.003
PMN 18 19 16 0.091
* Bidirectional ABO mismatches (n¼5) were not included in the analysis
Figure 3. Impact of chronic GVHD (cGVHD) on OS in 138 AML/MDS patients
who underwent RIC allo HCT.413
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Clinical Characteristics
Typical (n[51) Leaky, Omenn, RD (n[23)
Age at Dx (days) 27 52
Age at HCT (days) 101 (16-461) 145 (30-5137)
Genotype
ADA 2 0
AK2 0 2
Artemis 0 2
CD3d 3 0
IL2Rg 26 2
IL7R 5 0
JAK3 3 1
RAG 1, 2 7 11
RMRP 0 1
Zap70 0 1
Unknown 5 3
Donor
MRD 8 3
MMRD 16 1
Adult URD 12 13
UCB 16 6
Conditioning
None 17 1
Serotherapy-only 5 1
RIC 7 10
MAC (Bu > 8 mg/kg) 22 11
GVHD Prophylaxis
None 5 0
TCD 18 2
CI Only 3 2
CI + Other 25 19Oncology/Blood and Marrow Transplantation, University of
Minnesota Medical Center, Fairview, Minneapolis, MN; 23 The
Children’s Hospital of Philadelphia, Philadelphia, PA; 24Children’s
National Medical Center, Washington, DC; 25 Institute for Pediatric
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Angeles, Los Angeles, CA; 28 Laboratory of Host Defenses, National
Institutes of Health, Bethesda, MD; 29University of San Francisco,
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We report interim evaluation of the 1st 74 patients who
underwent HCT on Protocol 6901, a natural history study to
identify variables associated with overall survival (OS) &
immune reconstitution in SCID. From 8/2010 e 5/2013, pa-
tients from 21 centers underwent diagnostic work-up &
therapy according to local practice (Table 1). Consenting
patients were centrally reviewed & assigned to typicalFigure 2.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S291SCID or leaky SCID/Omenn Syndrome, or Reticular
Dysgenesis(RD).
Survivors had at least 1y follow up. OS at 1y was 88% (63/74).
Grade 2-4 aGVHD was seen in 19%, Grade 3-4 aGVHD in 8% &
cGVHD in 17% by 1y. A 2nd HCT was needed in 6 patients by
1y. Of these, 5/6 survived. Initially 5 received no condition-
ing/serotherapy vs. 1 who received RIC/MAC (p ¼ 0.005).
Leaky SCID/Omenn had similar 1y OS to typical SCID (86% vs.
92%; p ¼ 0.212; Fig 1). Both patients with RD died. By donor
type 1y OS was 100% for MRD; 94% for MMRD; 84% for URD &
73% for UCB. Mortality was similar irrespective of condi-
tioning: 13% no conditioning/serotherapy; 18% RIC; 15%MAC.
Mortality was due to infection [CMV (3), EBV PTLD (1), RSV/
PCP (1), Trichosporon (1) & Enterococcus (1)] and, seen only
in MAC, HCT complications [VOD (3), encephalopathy (1)].
At 1y, median CD3 chimerism was >98% regardless of con-
ditioning. Use of RIC/MAC vs no conditioning/serotherapy
was associated with better median lineage speciﬁc donor
chimerism in CD19 (99% vs 10%; p ¼ 0.005) & myeloid cells
(97% vs 1%; p <0.001) & trended toward freedom from IVIG
(43% vs. 17%; p ¼ 0.056). In typical SCID median CD4 counts
were higher in those receiving RIC/MAC (1482 vs 878; p ¼
0.022; Fig 2). In cohort-wide comparison of HCT with vs
without conditioning, median CD4 count (1345 vs 855), %
CD45RA (43 vs. 40) & PHA response (both 100%) were not
signiﬁcantly different.
Survival of patients with typical SCID & leaky SCID/Omenn
after HCT was high, but problems remained. Deaths were
most commonly related to infection, but a 3rd were attrib-
utable to conditioning toxicities, in particular VODwithMAC.
This emphasizes need to minimize busulfan use. Condition-
ing improved certain aspects of immune reconstitution at 1y
& decreased need for 2nd HCT. GVHD affected w1 in 5 in-
fants. Future efforts to decrease GVHD & establish safer
chemotherapy exposure in very young infants requiring
conditioning are needed to improve outcomes. Longer-term
follow-up of these patients will identify factors that impact
late effects & quality of life post HCT for SCID.
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The last two decades have seen Donor Lymphocyte Infusion
(DLI) emerge as a treatment option for disease relapse
following allogeneic stem cell transplant. Reviewing the
literature reveals a great degree of variability in how DLI is
performed. One trend is to use G-CSF-mobilized stem cells
instead of conventionally collected stem cells. It is alsounclear whether the type of cells utilized, fresh versus cry-
opreserved, impacts the DLI efﬁcacy.
We identiﬁed all patients who underwent DLI for persistent
or relapsed disease at the Temple BMT Unit between 7/1993
and 12/2013. We determined response to DLI per standard
criteria to calculate event free survival (EFS) and overall
survival (OS), post-DLI. Correlative calculations were con-
ducted between DLI and pre-transplant conditioning
regimen [Myeloablative vs. Non-Myeloablative], DLI condi-
tioning regimen [if any], # of CD3+ cells infused, absence or
presence of post-DLI GVHD and interval between original
transplant and disease progression with respect to EFS
and OS.
We identiﬁed 63 patients who received DLI for persistent or
relapsed disease. Median F/U was 5.4 years (range 0.03-
11.88). The OS was similar between the cryopreserved and
fresh cells groups [median OS for cryopreserved¼0.39 yrs,
median OS for fresh¼0.32 yrs; p¼0.79] [Fig 1A]. Type of pre-
transplant conditioning [myeloablative versus non-myelo-
ablative] had no impact on OS [for myeloablative, p¼0.52; for
non-myeloablative, p¼0.12]. The EFS was similar between
the two groups [median EFS for cryopreserved¼0.41 yrs,
median EFS for fresh¼0.42 yrs; p¼0.43] [Fig 1B]. Analysis
based upon pre-transplant conditioning resulted in similar
EFS values [for myeloablative, p¼0.98; for non-myelo-
ablative, p¼0.14]. Presence or absence of GVHD post-DLI had
no impact on OS or EFS [n¼55, p¼0.5]. The dose of CD3+
cells infused for each DLI [median dose ¼ 5.00E7cells,
range¼2.00E6-5.20E8] had no correlation with OS [p¼0.13]
or EFS [p¼0.3]. The interval between original transplant and
